SUMMARY Serum from patients with juvenile chronic arthritis (JCA) was shown to inhibit colony formation by normal erythropoietic progenitor cells cultured in vitro. The inhibition was proportional to the degree of anaemia and to certain indices of activity of the arthritis and systemic disease. It and erythroid aplasia4 to be causative factors in some patients, but in the majority no specific aetiology is demonstrated, and it is ascribed to the anaemia of chronic inflammatory disease'.5 There has been no investigation of this type of anaemia in children, but in adults with rheumatoid arthritis we have recently described a serum inhibitor of in vitro erythropoiesis.'
Juvenile chronic arthritis (JCA) is the term used to describe a heterogeneous group of arthritic disorders of childhood' in which anaemia is a common manifestation. The degree of the anaemia is related to the severity and type of the disease.2 Previous reports have shown iron deficiency,3 haemolysis,2 and erythroid aplasia4 to be causative factors in some patients, but in the majority no specific aetiology is demonstrated, and it is ascribed to the anaemia of chronic inflammatory disease'.5 There has been no investigation of this type of anaemia in children, but in adults with rheumatoid arthritis we have recently described a serum inhibitor of in vitro erythropoiesis.'
Techniques now available for in vitro culture of haemopoietic progenitor cells permit detailed investigation of the physiology of normal erythropoiesis and also of the mechanisms of such putative inhibition. The colony forming assay in semisolid medium allows differentiation and proliferation of primitive and more mature erythroid progenitor cells from the bone marrow. Small colonies of the more mature cell type develop after seven days in culture (colony forming unit erythroid, CFU-e), while large multicentric colonies of the more primitive cell (burst forming unit erythroid, BFU-e) develop after 14 days.7 BFU-e, but not CFU-e, can also be cultured from peripheral blood mononuclear Accepted for publication 14 July 1986. Correspondence to Dr Pctcr J Prousc Division of Rheumatology.
Northwick Park Hospital. Watford Road, Harrow. Middlesex. cells. 8 Optimal colony formation requires the presence of accessory cells, monocytes/macrophages, and T lymphocytes or their secreted products during the very early stages of differentiation and proliferation,9 lt whereas erythropoietin is active primarily on more mature erythroid precursors.
In a number of bone marrow failure states (pure red cell aplasia, aplastic anaemia) clonal assays have implicated inhibition of haemopoietic progenitors in the pathogenesis.'" Humoral inhibitors and suppressor lymphocytes have been demonstrated, and macrophages have been claimed to inhibit erythropoiesis in the anaemia of chronic infection. Recently, inhibition of BFU-e growth in vitro has been demonstrated in anaemic adult patients with rheumatoid arthritis (RA),/ and other evidence for such a mechanism has been put forward.13 14 The object of this study was to examine the effect of serum from patients with JCA on normal erythroid progenitors and to seek to correlate this with the severity of the anaemia and disease activity. An additional study of JCA bone marrow cells in culture was performed to investigate whether progenitor cell-accessory cell interactions were normal and to examine the effect of autologous serum on marrow BFU-e development. (17) , sodium aurothiomalate (two), auranofin (two), chloroquine (four), D-penicillamine (three), and chlorambucil (two) ( Table 1) .
PERIPHERAL BLOOD STUDIES
Sera from the 31 patients with JCA were screened for inhibitory activity in the BFU-e colony forming assay by one of us (PJP) without knowledge of the clinical data. Group 0 peripheral blood mononuclear cells from five normal volunteers were prepared by Ficoll-Paque centrifugation, and after incubation in plastic tissue culture plates the nonadherent cell fraction (PB-NAC; <5% macrophages present) was used as the source of erythroid progenitors (BFU-e) in methylcellulose culture at 5 x 105 cells/ml. Serum autologous with the PB-NAC or sera from patients with JCA were added at 10% final volume. Sera from five selected patients were titrated at varying saline dilutions to define the doseresponse relationship of the serum inhibitor. BFU-e colonies were counted at 14 days by direct vision using an inverted microscope. Myeloid colonies (CFU-GM), identified by distinct morphology and absence of haemoglobin, were also counted at 14 days. BFU-e and CFU-GM counts were obtained from simultaneous cultures of PB-NAC with autologous or JCA sera; the counts obtained with autologous serum were designated as a standard 100%, and the counts obtained with JCA sera as a proportion of that (percentage growth, Table 1 ).
The mean colony count in control cultures for BFU-e was 50 (range 28-69) and for CFU-GM was 6 (range [3] [4] [5] [6] [7] [8] the clinical and laboratory variable indices of disease activity was assessed for each patient by the linear regression method. In addition, using the GLIM computer program'8 14 explanatory variables were investigated in various combinations to try to find a function that best fitted the observed percentage growth. The GLIM computer program is a generalised multiple regression method which was chosen to allow the various possible combinations of these variables to be considered in a multivariate way; to examine each one separately when the others were also involved could be seriously misleading. Vari- (Fig. ld) , but the reduction in growth did significantly correlate with the overall assessment of disease activity ( Table   2 ). The percentage growth for each serum sample is recorded in Table 1 , and the individual relationships between percentage growth and Hb, CRP, IgG, and joint count are illustrated in Fig. 1 . Further analysis of the variables listed in Table 1 by the GLIM program showed that the observed percentage BFU-e growth was best predicted by five factors: joint count (p=0-020), haemoglobin (p=0-029), IgG (p=0-020), sodium aurothiomalate Addition of increasing concentrations of known inhibitory serum to normal peripheral blood cultures produced increasing inhibition of BFU-e development (Fig. 2) . This dose-response relationship is that of an inhibitor and would not be the result of the failure of normal serum stimulators of BFU-e.
The reproducibility of inhibition was tested by comparing the effect of sera from 10 of the 31 patients on mononuclear cells from separate donors, and a comparable degree of inhibition was found (Table 3) .
Enumeration of myeloid colonies (CFU-GM) failed to show a reduction in numbers by patient serum that correlated with either the haemoglobin level (Table 1) or with disease activity (Table 2) . In the three anaemic JCA patients from whom bone marrow aspirates were taken the influence of autologous serum on BFU-e growth was compared with that of heterologous ABO matched normal serum. BFU-e numbers both from the BM-NAC and LDF cell pools were reduced by autologous serum. Pooling the results from all six cultures showed the reduction in growth to be significant ( (Figs 3a and b) . This is in agreement with our findings in RA that autologous accessory cells were not deficient in providing growth factors. 6 Inhibition of erythropoiesis corresponded with the severity of the anaemia and also with the disease activity, implying that it is produced as an integral part of the inflammatory process. The patients with JCA and with the greatest degree of serum inhibition were those with active systemic disease, many of whose features are also thought to be mediated by interleukin 1.38 Interleukin 1,  however, is highly unlikely to inhibit in vitro erythropoiesis by making iron unavailable, as excess iron is present in the culture medium and inhibition occurs when there are only low numbers of macrophages present in the cultures.
Clarification of the precise mechanisms of serum inhibition of erythropoiesis in JCA will require detailed studies using highly purified progenitor cell and accessory cell populations to elucidate the target cell and fractionation of the serum to permit physicochemical identification of the factor(s) responsible.
